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ABSTRACT 
Purpose: The natural flavonoid fisetin was recently identified as a lead compound that 
stabilizes endothelial cell microtubules. In this study we investigated the antiproliferative and 
antiangiogenic properties of fisetin in vitro and in vivo.  
Methods: Fisetin cytotoxicity was evaluated using Lewis lung carcinoma cells (LLC), 
endothelial cells and NIH 3T3 cells. Endothelial cell (EC) migration and capillary-like 
structure formation were evaluated using EAhy 926 cells. In vivo tumour growth inhibition 
studies were performed using LLC bearing mice treated with fisetin and/or cyclophosphamide 
(CPA).  
Results: The fisetin IC50 was 59 µM for LLC and 77 µM for EC cells, compared to 210 µM 
for normal NIH 3T3 cells (24 h). Fisetin inhibited EC migration and capillary-like structure 
formation at non-cytotoxic concentrations (22-44 µM). In mice, fisetin inhibited angiogenesis 
assessed using the Matrigel plug assay. In LLC bearing mice, fisetin produced a 67% tumour 
growth inhibition (223 mg/kg, intraperitoneal), similar to the 66% produced by low dose CPA 
(30 mg/kg, subcutaneous). When fisetin and CPA were combined, however, a marked 
improvement in antitumour activity was observed (92% tumour growth inhibition), with low 
systemic toxicity. Tumour histology showed decreased microvessel density with either fisetin 
or CPA alone, and a dramatic decrease after the fisetin/CPA combination.  
Conclusions: We have shown that fisetin not only displays in vitro and in vivo 
antiangiogenic properties, but that it can also markedly improve the in vivo antitumour effect 
of CPA. We propose that this drug combination associating a non-toxic dietary flavonoid with 
a cytotoxic agent could advantageously be used in the treatment of solid tumours. 
 
Keywords: flavonoid, fisetin, cyclophosphamide, Lewis lung carcinoma, EA⋅hy 926 
endothelial cells, angiogenesis, cytotoxicity, antitumour activity 
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Background  
Tumour vasculature is an attractive target for cancer therapy because a single vessel provides 
oxygen and nutrients to numerous tumour cells and is the main route for metastatic 
dissemination of cancer cells (reviewed in [1]). Tumour angiogenesis is the result of an 
imbalance between pro-angiogenic factors, e.g., vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and endogenous 
antiangiogenic factors, such as angiostatin and endostatin [2-4]. Tumour vasculature can be 
targeted at the angiogenesis level to prevent the formation of new vessels using 
antiangiogenic agents, or at the vascular level using vascular disrupting agents on already 
formed vessels [5,6]. The anti-angiogenesis approach has already proven its clinical 
effectiveness in colon, breast, and non-small-cell lung cancer using VEGF antibody in 
combination with cytotoxic drugs [7-9].  
 
Several phytochemicals, or compounds derived from edible plants, have been linked to the 
chemoprevention of cancer [10]. Among these compounds, the natural flavonoids have been 
shown to display pharmacological properties of interest in the prevention and treatment of 
cancer, as cytotoxic and/or as antiangiogenic agents [11-14].  
 
In a program aimed at finding novel antiangiogenic agents, we recently identified the natural 
flavonoid fisetin (3,3',4',7-tetrahydroxyflavone) as an interesting lead that can stabilize 
endothelial cells in vitro at non cytotoxic concentrations (Figure 1) [15]. Fisetin is present in 
several fruits, vegetables, nuts and wine [16,17], and displays a variety of biological effects 
including antioxidant, anti-inflammatory [18,19], anti-carcinogenic and in vitro anti-
angiogenesis [20]. Fisetin has already been shown to be cytotoxic to various human cancer 
cell lines including leukaemia (HL60) [21], breast (MCF7) [20], colon (HT29) [22], liver 
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(SK-HEP-1, Caco-2) [22,23], neuroblastoma (SHEP, WAC-2) [20], prostate (LNCaP, PC3) 
[24], and also to several endothelial cells [20]. Fisetin has been shown to inhibit several 
molecular targets, including cyclin-dependent kinases [25-27], DNA topoisomerases I and II 
[28,29], urokinase [30], actin [31], and androgen receptor signalling [32]. It has also recently 
been found that fisetin induces a forced exit from mitosis by targeting the mitotic spindle 
checkpoint involving the inhibition of Aurora B activities required for the maintenance of 
normal spindle checkpoint signalling [33].  
 
In the present study, we further tested fisetin’s in vitro antiangiogenic action and evaluated its 
in vivo antitumour activity in Lewis lung carcinoma bearing mice. We report here that fisetin 
displays anti-angiogenic properties in vitro as well as in vivo inhibition of Lewis lung 
carcinoma tumour growth involving an anti-angiogenic mechanism. In addition, when fisetin 
was combined with low dose cyclophosphamide, a remarkable improvement in antitumour 
activity involving an anti-angiogenic mechanism of action was observed. We propose that this 
relatively non toxic drug combination using a dietary phytochemical with low-dose 
cyclophosphamide could advantageously be used in the treatment of solid tumours. 
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Methods 
 
Chemicals 
Fisetin (3,3',4',7-tetrahydroxyflavone) and cyclophosphamide were purchased from Sigma-
Aldrich (Saint-Quentin Fallavier, France). Fisetin stock solution was prepared in 
dimethylsulfoxide (DMSO) and stored at 4°C in the dark. Cyclophosphamide was dissolved 
in sterile water.  
 
Cell viability 
The murine Lewis lung carcinoma (LLC) cell line, the NIH 3T3 murine fibroblast cell line 
and the EAhy 926 endothelial cell line (an immortalized human umbilical vein endothelial 
cell line [34]) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 2 mM 
L-glutamine, 10% foetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml 
streptomycin (37°C, 5% CO2). Exponentially growing cells were plated onto 96-well plates at 
5000 cells per well in 200 µl. After 24 hours, cells were exposed to fisetin at the indicated 
concentrations for an additional 48 h. Viability was assessed using the MTT (1-(4,5-
dimethylthiazol-2-yl)-3,5-diphenyltetrazolium) test and absorbance was read at 562 nm using 
a microplate reader (BioKinetics Reader, EL340). Appropriate controls with DMEM only and 
MTT were used to determine background absorbance. Experiments were run in quadruplicate 
and repeated 3 times. Control cells were exposed to 1% DMSO which was not cytotoxic. The 
results are presented as the inhibitory concentration for 50% of cells (IC50). 
 
Cell cycle analysis 
Lewis lung carcinoma and EAhy 926 endothelial cells were seeded in 6-well plates at 10
5 
cells/well. Twenty-four hours later, fisetin was added to the wells at the indicated 
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concentrations and the cells were incubated for 48 h. For each condition, detached and 
adherent cells were harvested, fixed for at least 30 min in 70% ethanol, and incubated with 
propidium iodide (50 µg/ml), sodium citrate (1 mg/ml) and RNase A (50 µg/ml) for 30 min in 
the dark. Nuclei DNA content was determined by flow cytometry (Coulter Epics Beckman, 
Germany) with red emission (FL-2 channel, 570 nm). After debris exclusion using 
forward/side scatter gating, 10
4
 nuclei were acquired and analyzed using the WinMDI 
software. Cells with sub-G1 DNA content were considered to be apoptotic. 
 
Cell migration assay (scratch wound assay) 
EAhy 926 endothelial cells were grown to confluence and a wound was introduced by 
clearing an area of the monolayer using a 100 µl pipette tip. Digital photographs of wounded 
areas were recorded from each well at a magnification of 100x (time 0 h). Following a change 
of medium, basic fibroblast growth factor (bFGF, 10 ng/ml, BD Biosciences) and fisetin at 
the indicated concentrations were added to the medium with 2.5% of FBS. After 24 h 
incubation, digital photographs of the wound areas were recorded for each well. Migration 
was evaluated by manually drawing the distance of the wound area (d) at T0h and T24h. 
Distance values were obtained using the ImageJ software [35]. Results were expressed as a 
percentage of the controls using the following formula: 100 × [1-(dT0h-dT24h of treated cells)/( 
dT0h-dT24h of control cells)]. Experiments were performed in triplicate for each concentration 
and were repeated 3 times. 
 
Formation of capillary-like structures 
Fifty µl of gel matrix solution was applied to each well of a 96-well plate and incubated for 30 
min at 37°C. EAhy 926 cells (1 × 10
4
) were suspended in 100 µl of medium, plated onto the 
gel matrix and incubated at 37°C. Adherent cells received bFGF (10 ng/ml) and fisetin at the 
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indicated concentrations. After a 24 h exposure time, in vitro angiogenesis was assessed by 
counting the number of capillary-like structures in each well at 100x magnification with a 
light microscope (Zeiss). The in vitro anti-angiogenic effect was calculated using the 
following formula: 100 × [1-(number of capillary-like tubes in treated cells) / (number of 
capillary-like tubes in control cells)]. Experiments were performed in duplicate for each 
condition and repeated 3 times. 
 
Animal experiments 
 
All animal experiments were ethically conducted, according to institutional, French and 
European guidelines, and were approved by the institutional animal welfare committee. 
 
a) Matrigel plug angiogenesis assay. Fifteen 6-week old C57BL/6J female mice (Janvier, Le 
Genest Saint Isle, France) were randomly divided into five groups. LLC cells were 
trypsinized and resuspended at 3 X 10
7
 cells/ml in serum-free medium. Aliquots of cells (0.1 
ml, 3 X 10
6
 cells) were mixed with 0.2 ml of phenol red-free Matrigel and injected into the 
right flank of mice. For the fisetin-treated groups, the cells were injected with four increasing 
concentrations of fisetin: 12.5, 25, 50 and 100 µg/ml (or 22, 44, 87, 175 and 350 µM). 
Controls included cells with equal volumes of solvent, whereas the Matrigel mixed with the 
medium alone was used as a negative control. The Matrigel plugs were removed 14 days after 
the implantation, weighed and measured for haemoglobin content using the Drabkin’s reagent 
kit according to the manufacturer’s instructions (Sigma-Aldrich). Haemoglobin concentration 
was calculated based on a set of haemoglobin standards. The data are presented as mean ± 
SEM from triplicate experiments.  
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b) Evaluation of antitumour activity in mice. In preliminary experiments with non 
tumoured C57BL/6J female mice, fisetin at 223 mg/kg intraperitoneally (i.p.) was found non 
toxic (based on body weights) when administered for 5 consecutive days in week 1 and for 5 
consecutive days in week 2. Fisetin was dissolved in polyethylene glycol 200 
(PEG200)/DMSO (7:3; v:v) and injected i.p. in a volume of 0.1 ml. For antitumour evaluation, 
Lewis lung tumour fragments (about 3 mm
3
) were injected subcutaneously (s.c.) bilaterally 
into mouse flanks. Tumour growth was assessed every 2 days using bi-dimensional 
measurements with a caliper. Tumour volume (mm
3
) was calculated according to the formula: 
width
2
 × length × 0.5 (mm). In the first experiment, fisetin was injected i.p. into 5 tumoured 
mice at 223 mg/kg on days 5 to 9 and days 12 to 16 post tumour implantation. In a second 
experiment, 20 mice were randomly divided into 4 groups. Fragments of LLC tumour (3 
mm
3
) were injected bilaterally s.c. into the mouse flanks, and 4 days after tumour 
implantation, the mice were submitted to the following treatments: mice in the fisetin group 
were injected i.p. on days 4 to 8, 11, 12, and 14 with 223 mg/kg of fisetin dissolved in a 0.1 
ml volume of PEG200/DMSO (7:3; v:v); mice in the cyclophosphamide group were injected 
s.c. on days 4, 5, 7 and 8 with 30 mg/kg of cyclophosphamide dissolved in water; mice in the 
combination group were treated with both fisetin and cyclophosphamide as described above; 
mice in the control group were injected with both vehicles. The 30 mg/kg dose 
cyclophosphamide was based on previous work that showed that doses of 10-40 mg/kg can be 
administered daily for prolonged period without undue toxicity [36]. For comparison 
purposes, the maximum tolerated dose of cyclophosphamide in mice is between 186 to 220 
mg/kg when administered as a single dose [37,38] and 170 mg/kg when given every 6 days 
[39]. Therefore, the 30 mg/kg dose for 4 days used in our experiments can be considered a 
low cyclophosphamide dose that was not toxic, based on body weight data. Tumour 
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measurements were recorded three times weekly; the mice were euthanized 15 days after 
tumour inoculation.  
 
Microvessel density evaluation 
Tumour tissues were harvested, weighed, frozen in isopentane, immersed in liquid nitrogen, 
and stored at –70°C until preparation of the histology slides. Ten-micron frozen tissue 
sections were placed on Superfrost Plus slides. Immunostaining of PECAM-1 (monoclonal rat 
antibodies anti-PECAM-1 (platelet endothelial cell adhesion molecule 1), clone MEC13.3; 
BDPharmingen, Le Pont-De-Claix, France) was performed using a three-step procedure as 
previously described [40]. In brief, the sections were washed three times in 1X phosphate 
buffered saline (PBS) and incubated for 10 min in 0.3% hydrogen peroxide/PBS. The slides 
were washed three times with 1X PBS, and incubated with 1% bovine serum albumin (BSA) 
at room temperature for 30 min. The sections were incubated with the rat primary antibodies 
anti-PECAM-1 (1:50) in a humidified chamber at 37°C for 1 h. After three washes in PBS, 
the slides were incubated for 30 min with biotinylated-secondary antibody with goat anti-rat 
IgG (1:400). After 3 rinses, slides were again incubated with the streptavidin-conjugated 
peroxidase according to the manufacturer’s instructions (dilution 1/400). The 3,3’-
diaminobenzidine (DAB) substrate was then added for 5 to 7 min until a brown precipitate 
was visible. Sections were rinsed several times in 1X PBS. Sections incubated with BSA 
instead of the primary antibodies were used as negative controls. Slides were counterstained 
with Gill’s haematoxylin and treated with a 25% ammonia solution to generate a blue nuclear 
stain, dehydrated in graded ethanol solutions and xylene, and mounted with Eukit®. 
Microvessel density was evaluated under the microscope by counting 3 fields at a 
magnification of 100x on two different slides. Microvessel density was expressed as the 
number of PECAM-1 positive microvessels per mm². 
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Statistical analyses 
Results are expressed as the mean ± SEM of at least 3 independent experiments. Comparisons 
between means were assessed using the Student t test for unpaired data. If unequal variance 
was observed, Welch's correction was applied. Comparisons between several groups were 
assessed using a one-way analysis of variance (ANOVA) followed by the Dunnett's multiple 
comparison test, using an appropriate control group as the reference. The statistical analyses 
were performed using the GraphPad Prism software. A P value < 0.05 was considered 
significant. 
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Results 
Fisetin effects on cell viability, cell cycle and apoptosis of Lewis lung carcinoma (LLC) 
cells, endothelial cells (EAhy 926), and normal cells (NIH 3T3) 
 
Fisetin induced a dose-dependent decreased viability in both Lewis lung carcinoma (LLC) 
and endothelial cells (EAhy 926), with IC50s of 59 and 77 µM, respectively, for a 24-h 
exposure time (Table 1). Interestingly, normal NIH 3T3 cells were found 3 times less 
sensitive to fisetin than either LLC or endothelial cells, with an IC50 of 210 µM (Table 1). 
When the incubation time was increased to 48 h, the differential sensitivity between normal 
NIH 3T3 cells and LLC or EAhy 926 cells reached a 5-fold difference. 
 
To characterize the mechanism of the cytotoxic/antiproliferative effect of fisetin, apoptosis 
was analyzed on LLC and endothelial cells. Table 2 shows the DNA cell cycle and sub G1 
distribution of fisetin-treated cells after 48 h exposure at the indicated concentrations. Fisetin 
induced apoptosis in a dose-dependent manner in LLC cells, as measured by cells with sub-G1 
DNA content. At low concentrations (22 and 44 µM), fisetin induced apoptosis in 5% of LLC 
compared to 1% in control cells. Higher fisetin concentrations (175-350 µM) induced higher 
levels of apoptosis (29%). Fisetin also induced a dose-dependent decrease in cells in G1. All 
tested concentrations of fisetin induced an accumulation of cells in the G2/M phase (25-36%) 
compared to controls.  
 
The fisetin effects on the cell cycle distribution of EAhy 926 endothelial cells differed 
markedly from the LLC cell line. Indeed, at low concentrations (22 and 44 µM), fisetin 
already induced a higher percentage of apoptotic cells (11-15%), and at high fisetin 
concentrations (175 and 350 µM) high levels of apoptosis were achieved (38% and 60%, 
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respectively). As sub-G1 apoptosis increased, the percent of cells in G1, S and in G2/M phases 
decreased (Table 2). Contrary to LLC cells, no accumulation of fisetin-treated endothelial 
cells was observed in the G2/M phase. 
 
Fisetin inhibits angiogenesis in vitro 
 
a) Effect of fisetin on migration of EAhy 926 endothelial cells. We next examined the 
possible antiangiogenic effects of fisetin on endothelial cell migration by using the scrape 
wound assay. Figure 2 illustrates that at 24 h post-wounding of confluent EAhy 926 
endothelial cells, control cells migrated and totally filled the scraped area. Fisetin exposure at 
22 and 44 µM (24 h), however, resulted in a significant dose-dependent decrease in EAhy 926 
endothelial cell migration. The calculated IC50 for the anti-migration effect was 45 ± 0.3 µM 
(mean ± SEM from 3 independent experiments).  
 
b) Effect of fisetin on capillary-like structure formation on Matrigel. The endothelial cell 
tube formation assay was used to investigate fisetin anti-angiogenesis effect in vitro. EAhy 
926 endothelial cells plated on Matrigel with bFGF formed a capillary-like network within 24 
h, as expected (Figure 3). Fisetin at 22, 44 and 87 µM prevented the formation of the 
capillary-like network in a dose-dependent fashion. The calculated IC50 for the inhibition of 
capillary-like structure formation was 52 ± 7 µM (mean ± SEM from 3 independent 
experiments). 
 
Fisetin inhibits angiogenesis in vivo 
We then investigated fisetin tumour angiogenesis in vivo. LLC cells were mixed with 
Matrigel with increasing concentrations of fisetin (44 to 350 µM) and injected s.c. into the 
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right flank of mice. Fourteen days later, the mice were sacrificed and the Matrigel plugs 
removed, weighed, and evaluated for haemoglobin content. The Matrigel plugs were 
significantly smaller in the fisetin-treated groups compared to the controls. Matrigel plug 
weights decreased significantly as fisetin concentrations increased (Figure 4-A). To quantify 
angiogenesis, the haemoglobin content of the Matrigel plugs was assayed. As shown in Figure 
4-B, fisetin treatment led to a dose-dependent decrease in Matrigel plug haemoglobin levels, 
which became significant at 350 µM. These in vivo results indicate that fisetin can decrease 
tumour angiogenesis. 
 
Fisetin antitumour activity in vivo 
To determine whether fisetin could inhibit tumour growth in vivo, fisetin was administered to 
two groups of 5 LLC tumour-bearing mice. Mice in the treated group were injected i.p. with 
fisetin at 223 mg/kg for 5 consecutive days during week 1, and for another 5 consecutive days 
in week 2. Mice in the control group received solvent on the same days as the fisetin-treated 
group. Preliminary experiments showed that fisetin alone was not toxic at this dose level and 
schedule of administration. On day 15, tumours from the mice treated with fisetin were 50% 
smaller than control tumours and appeared less vascularized than the controls (data not 
shown).  
 
In vivo antitumour activity of the combination of fisetin and cyclophosphamide 
To optimize the in vivo anticancer effect of fisetin found above, fisetin was next combined 
with low dose cyclophosphamide, a cytotoxic drug reported to possess antiangiogenic 
properties [39]. Fisetin was administered i.p. at 223 mg/kg daily for 5 days in week 1 (days 4 
to 8 post tumour implantation), followed by three injections on days 11, 12 and 14 (Figure 5, 
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triangles). Fisetin treatment led to a 67% tumour growth inhibition compared to the controls 
(squares). Low dose cyclophosphamide was administered s.c. at 30 mg/kg on four days in 
week 1 only (days 4, 5, 7, 8), and led to a tumour growth inhibition of 66%, similar to fisetin 
treatment (Figure 5, diamonds). When fisetin and cyclophosphamide were combined at the 
same dose levels and schedules as used above, tumour volumes declined dramatically, 
showing 92% inhibition compared to controls on day 15 (Figure 5, solid circles). Over the 
two week treatment, this drug combination was not toxic, showing only a 4.6% loss in body 
weight, similar to that of the fisetin treatment alone (4.3%).  
 
In vivo fisetin antiangiogenic effect 
To verify if the in vivo tumour growth inhibition was due to an antiangiogenic effect, tumour 
sections were stained using PECAM-1 antibodies. PECAM-1 was mainly expressed in 
endothelial cell membranes of microvessels, as expected (Figure 6-A, Control). The number 
of microvessels expressing PECAM-1 in the fisetin- and in the cyclophosphamide-treated 
tumours was significantly diminished compared to those in the control (Figures 6-A and 6-B). 
However, the treatment with the fisetin and cyclophosphamide drug combination led to an 
impressive and significant decrease in microvessel density, as depicted in Figures 6-A and 6-
B. 
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Discussion 
 
Although several phytochemicals have been shown to possess pharmacological properties of 
potential interest in cancer prevention and/or therapy, their activity in the tumour angiogenic 
process is presently not well understood [10-14,20]. Because we recently identified the 
dietary flavonoid fisetin as an interesting lead that can stabilize the cytoskeleton of 
endothelial cells in vitro at non cytotoxic concentrations [15], we were therefore interested to 
evaluate the in vivo antiangiogenic activity of this compound. 
 
The fisetin antiproliferative/cytotoxic activity determined in this study on LLC and 
endothelial cells confirmed its cytotoxic activity reported on other cancer cell lines, e.g., in 
prostate [24], liver [23], colon [25], and leukaemia cells [21]. In this study, normal NIH 3T3 
cells were also found to be about 3-fold less sensitive to fisetin than LLC or endothelial cells. 
It is of interest that the fisetin relative selectivity towards cancer and endothelial cells, 
compared to normal cells, has also been observed in other studies [20], and this selectivity 
was also observed on prostate cancer cells that were shown to be more vulnerable to fisetin 
compared to normal prostate cells [24]. This relatively non frequent cancer cell selectivity 
could therefore confer a valuable advantage of this compound for in vivo treatment.  
 
We also observed that fisetin could block LLC cells in the G2/M phase at low concentrations, 
and could induce apoptosis in endothelial cells also at low concentrations. These observations 
would suggest that fisetin could first act in vivo on endothelial cells forming the tumour 
vasculature and then cause apoptosis of cancer cells in the vicinity of the blood vessel. 
Fisetin-induced G2/M cell accumulation has been previously reported along with decreased 
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activity of several cyclin-dependent kinases [21,23-25]. The signal transduction pathways 
involved in apoptosis include caspase 3 and increased p53 protein [23].  
 
Our data clearly show that fisetin possesses in vitro antiangiogenic effects, preventing both 
the migration of endothelial cells and the formation of capillary-like structures at low 
micromolar concentrations. Previous work on in vitro antiangiogenic effects of fisetin has 
reported this effect at similar concentrations [20].  
 
With regard to the relevance of the in vitro fisetin concentrations used in our experiments, the 
fisetin plasma concentrations achieved in mice are in the range of 10 µM after intraperitoneal 
administration of a dose of 223 mg/kg (Touil YS and Chabot GG, unpublished data). In rats, 
free fisetin plasma concentrations of 50 µM can also be achieved after an i.v. dose of 10 
mg/kg [41]. These plasma concentrations are therefore in the range of the concentration used 
in vitro to show the antiangiogenic effects with the aglycone (free fisetin). In addition, it 
should be mentioned that because of the presence of 4 OH substituents on the fisetin 
molecule, glucuronide and sulphate conjugates are also present at high concentrations in 
plasma [41] (Touil YS and Chabot GG, unpublished data), and these metabolites could also 
play a role in the overall antiangiogenic effects observed in vivo in mice. It is of interest that 
flavonoid sulphates and/or glucuronides of closely related flavonoids (e.g., morin and 
quercetin) have recently been shown to display superior bioactivities compared to their 
aglycones (free forms) [42]. It should also be mentioned that mouse tumours usually have a 
high beta-glucuronidase and sulfatase activities that could hydrolyze locally the conjugates to 
release the aglycone within the tumour, and therefore contribute to the local antitumour effect 
[43]. 
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We next investigated if these in vitro antiangiogenic effects could be translated in vivo using 
Lewis lung carcinoma bearing mice. Fisetin was found to cause significant tumour growth 
inhibition when used as a single agent at non toxic doses. The mechanism of action involved 
in the in vivo fisetin antitumour activity most likely involves an antiangiogenic effect, as 
evidenced by a significant reduction in microvessel density. Although fisetin’s antiangiogenic 
activity has been previously reported in vivo in rabbit eyes, it should be mentioned that it was 
by direct application of an emulsion containing fisetin on the cornea [44] and not by systemic 
administration, as in the present study. To our knowledge this report is the first describing the 
fisetin’s in vivo antiangiogenic activities after systemic administration in mice.  
 
In an attempt to improve fisetin’s in vivo antitumour effects, we next combined this flavonoid 
with low dose cyclophosphamide, because this cytotoxic agent has already been shown to 
improve antiangiogenic therapy [39,45]. This drug combination clearly led to an impressive 
improvement in antitumour effect with a 92% tumour inhibition at non toxic dosages of both 
agents. Although the fisetin-CPA drug combination is leading to a greater effect than either 
drug used alone, the magnitude of this effect could not be analyzed using the Chou and 
Talalay’s method because measurements made with single doses of either drug in a 
combination can never alone determine synergism since the sigmoidicity of dose-effect 
curves and the exclusivity of drug effects cannot be determined from such measurements [46]. 
Because our data present only one dose level of either drug, we therefore cannot claim 
synergism, although there was a marked improvement in the anticancer activity of either drug 
at the single dose level used, as evidenced by tumour growth curves. Moreover, the 
histological examination of the treated tumours clearly showed that the microvessel density 
was significantly reduced in the tumours of mice that received the drug combination, thus 
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showing that an antiangiogenic effect was indeed involved in this impressive antitumour 
activity.  
 
The precise molecular mechanism of action of the increased antitumour and antiangiogenic 
activity observed with the fisetin-cyclophosphamide drug combination is not precisely known 
for the moment. Although the antiangiogenic action of each compound alone is probably 
playing a major role in the improved activity of the combination, other factors could also be 
involved. For instance, a pharmacokinetic interaction would be possible, as was shown for the 
drug combination involving thalidomide and cyclophosphamide [37]. However, it should be 
mentioned that such a pharmacokinetic interaction was observed at a high dose of 
cyclophosphamide (220 mg/kg) [37], which is a 7-fold higher dose that the one used in the 
present study (30 mg/kg). Further studies will have to address this issue. 
 
In addition to the stabilization of endothelial cells cytoskeleton [15], the antiangiogenic effect 
of fisetin and consequent antitumour activity could also involve the inhibition of urokinase 
plasminogen activator (uPA) in endothelial cells, as was recently reported [30]. UPA is over 
expressed in tumour vessels and is involved in extracellular matrix degradation responsible 
for endothelial cell migration and formation of new tumour blood vessels [47]. In addition to 
the Lewis lung carcinoma model, it is of interest to note that fisetin has recently been reported 
to be active in prostate cancer xenografts in nude mice through the inhibition of androgen 
receptor signalling, although angiogenesis was not investigated in this study [32]. Other 
potential mechanisms of action could involve the direct or indirect inhibition of other factors 
involved in the complex tumour angiogenic process. 
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Conclusions  
The data reported here provide the first evidence that the dietary flavonoid fisetin can display 
antiangiogenic and anticancer activities in vivo in mice bearing Lewis lung carcinoma. In 
addition, the remarkable improvement in the anticancer and antiangiogenic activities of the 
combination of fisetin with low dose cyclophosphamide deserves further studies given the 
fact that cyclophosphamide is used in several anticancer drug regimens. Optimization of this 
drug combination by improved scheduling and/or pharmaceutical formulations is therefore 
warranted. It is proposed that the relatively non toxic drug combination studied in this work, 
associating a natural compound and a cytotoxic agent, could be useful in the treatment of 
solid tumours. 
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Table 1 – Inhibitory concentration for 50% (IC50) of Lewis lung carcinoma cells (LLC), 
EAhy 926 endothelial cells and normal NIH 3T3 cells. Cells were exposed to fisetin at 
various concentrations for 24 or 48 h, and viability was evaluated by the MTT test. Mean ± 
SEM of 3 independent experiments each performed in quadruplicate. Statistical significance 
assessed by one-way analysis of variance followed by the Dunnett’s multiple comparison test, 
using the IC50 of NIH 3T3 cells as the reference. * = P < 0.001 
 
Inhibitory concentration for 50% (IC50) of cells (µM)  
Incubation time (h) LLC EAhy 926 ,ormal ,IH 3T3 
24 59 ± 9* 77 ± 9* 210 ± 14 
48 27 ± 0.3* 28 ± 0.3* 136 ± 13 
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Table 2 – Cell cycle analysis of Lewis lung carcinoma and EAhy 926 endothelial cells 
treated with fisetin. Cells were exposed to the indicated concentrations of fisetin for 48 h. 
Cells were harvested, fixed, incubated with propidium iodide and analyzed by flow 
cytometry. Mean ± SEM of 3 independent experiments. 
Percent cell in the indicated phase 
Cell line 
Fisetin 
Conc 
(µM) 
SubG1 G1 S G2/M 
0 1 ± 1 70 ± 1 14 ± 0.4 15 ± 1 
22 5 ± 1 51 ± 1 19 ± 0.3 25 ± 1 
44 5 ± 0.1 39 ± 1 22 ± 1 34 ± 1 
87 12 ± 0.1 26 ± 1 26 ± 1 36 ± 1 
175 29 ± 1 13 ± 1 31 ± 0.3 27 ± 2 
Lewis Lung 
Carcinoma cells 
350 29 ± 1 14 ± 1 29 ± 0.1 28 ± 0.3 
0 4 ± 1 66 ± 2 18 ± 1 12 ± 2 
22 11 ± 2 67 ± 0.6 11 ± 1 11 ± 2 
44 15 ± 1 65 ± 1 12 ± 1 8 ± 0.3 
87 35 ± 2 52 ± 0.4 9 ± 1 4 ± 1 
175 38 ± 1 49 ± 1 8 ± 1 5 ± 2 
EAhy 926 
endothelial cells 
350 60 ± 0.3 31 ± 1 7 ± 1 2 ± 1 
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Figure legends 
 
Figure 1 – Chemical structure of fisetin (3,3’,4’,7-tetrahydroxyflavone). 
 
Figure 2 – Effect of fisetin on cell migration (scratch wound assay). EAhy 926 
endothelial cells were grown to confluence and an area was cleared using a 100 µl pipette tip 
as described in the Methods. Digital photographs were recorded at a magnification of 100 X 
immediately after the wounding (Time= 0) and at 24 hours (T= 24 h) after the addition of 
bFGF (10 ng/ml) for the control, or with bFGF plus the indicated concentration of fisetin. 
Scale bar, 40 µm. 
 
Figure 3 – Effect of fisetin on capillary-like structure formation. EAhy 926 endothelial 
cells were grown on Matrigel with bFGF (10 ng/ml) in absence (control), or presence of the 
indicated fisetin concentrations for a 24-h incubation period. Digital photographs recorded at 
a magnification of 100 X. Scale bar, 20 µm. 
 
Figure 4 - In vivo Matrigel plug angiogenesis assay. Matrigel plugs containing Lewis lung 
carcinoma cells were implanted s.c. in mice with solvent (control=CTL) or with the indicated 
concentrations of fisetin. Fourteen days later, the Matrigel plugs were removed and weighed 
(A), and the content in haemoglobin was assessed (B), as described in the Methods.  * P value 
< 0.05 and ** P value < 0.01 compared to controls (Dunnett’s t test). The bar indicated 
“Matrigel” indicates the control without Lewis lung carcinoma cells. Error bars, SEM. 
 
Figure 5 - In vivo antitumour activity of the combination of fisetin with 
cyclophosphamide. Twenty mice bearing bilateral Lewis lung tumours were randomly 
assigned to four groups of 5 mice as follows: control, solvent alone (squares); fisetin, 223 
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mg/kg i.p. on days 4 to 8 and days 11, 12, 14 (triangles); cyclophosphamide, 30 mg/kg s.c., on 
days 4, 5, 7, 8 (diamonds); and, the combination of cyclophosphamide and fisetin (solid 
circles), both administered at the same dose and schedule when used alone. Tumour volumes 
were determined as described in Materials and Methods. Mean ± SEM. The * indicates a 
significant difference (P<0.05) with the Control group, and the # indicates a significant 
difference with the Fisetin or the Cyclophosphamide group (ANOVA and Dunnett’s multiple 
comparison test). 
 
Figure 6 – Evaluation of microvessel density in Lewis lung carcinoma tumours. A) 
Immunohistochemical evaluation of microvessels in Lewis lung tumours using antibodies to 
PECAM-1 as described in the Methods section. The tumours were treated in vivo with fisetin 
or cyclophosphamide alone, and with the combination of cyclophosphamide and fisetin. Scale 
bar, 100 µm. B) Microvessel density (number of vessels per mm²) in tumours after in vivo 
treatment with the solvent alone (control), with fisetin or cyclophosphamide (CPA) alone, or 
with the combination of fisetin and cyclophosphamide (CPA). Mean ± SEM. The asterisks 
indicate a P value < 0.05 compared to controls (Dunnett's multiple comparison test).  
 
Figure 1, Touil et al.
OOH
O
OH
OH
OH
3'
4'
3
7
Figure 2, Touil et al.
T = 24h
T = 24h
T = 24h
T = 0
T = 0
T = 0
Control
Fisetin 44 µM
Control
Fisetin 44 µM
Fisetin 22 µMFisetin 22 µM
_40 µm
__20 µm
Control
Fisetin 87 µMFisetin 44 µM
Fisetin 22 µM
Figure 3, Touil et al.
Figure 4, Touil et al.
M
at
ri
ge
l a
lo
ne
C
on
tr
ol
12
.5
 µ
g/
m
l
25
 µ
g/
m
l
50
 µ
g/
m
l
10
0 
µg
/m
l
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
**
*
**
M
a
tr
ig
el
 p
lu
g
 w
ei
g
h
t 
(g
)
A
B
CTL         44          87         175        350 µM
0
2
4
6
8
10
*
M
a
tr
ig
el
 p
lu
g
 h
em
o
g
lo
b
in
co
n
ce
n
tr
a
ti
o
n
 (
m
g
/g
)
Matrigel   CTL      44        87        175      350 µM
Figure 5, Touil et al.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
100
200
300
400
500
600
700
800 Control
Fisetin
Cyclophosphamide + Fisetin
Cyclophosphamide
Days post-implantation
T
u
m
o
r 
v
o
lu
m
e 
(m
m
3
)
Cyclophosphamide
30 mg/kg (s.c)
Fisetin
223 mg/kg (i.p.)
#
#
* *
* 
* **} }
Figure 6, Touil et al.
Control Fisetin
Fisetin+CyclophosphamideCyclophosphamide
____100 µm
A
B
C
on
tr
ol
Fi
se
tin
C
PA
C
PA
 +
 F
is
et
in
0
5
1 0
1 5
2 0
2 5
3 0
* * * *
* *
M
ic
ro
v
es
se
l 
d
en
si
ty
(
o
. 
m
ic
ro
v
es
se
ls
/m
m
²)
